{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:40:39Z","timestamp":1697866839346},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":8236,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1984,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peptichemio (PTC), a multipeptidic complex of m\u2010L\u2010phenyl\u2010alanine mustard, was administered to 39 children with neuroblastoma at relapse. The compound was given in two 5\u2010day cycles at dosages varying from 1.0\u20101.5 mg\/kg\/day. We were able to evaluate 29 of the initial 39 children for PTC effect; 21 of them had received PTC as first therapy following diagnosis. Ten patients underwent other chemotherapy for relapse before PTC. Three patients were off therapy when relapse occurred.<\/jats:p><jats:p>Subjective improvement was observed in 18 cases (62%). Eleven patients (38%) experienced an objective regression, which was scored as complete response in three cases, partial response in two, mixed response in six. In ten children no significant disease change was observed; the remaining eight had a progression of their disease while receiving PTC. The incidence of responses has been higher in patients off therapy at moment of relapse, and lower in those pretreated for their relapse. Previous administration of PTC did not reduce the chance of response at relapse.<\/jats:p><jats:p>Major toxic effects were transient, mostly moderate myelodepression and phleboscle\u2010rosis. Allergic reactions, nausea, and vomiting, occurred in a few patients.<\/jats:p><jats:p>These data indicate that PTC may exert objective antitumor activity in approximately one\u2010third of neuroblastoma patients at relapse.<\/jats:p>","DOI":"10.1002\/mpo.2950120303","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T15:36:14Z","timestamp":1171985774000},"page":"162-165","source":"Crossref","is-referenced-by-count":2,"title":["Peptichemio in neuroblastoma at relapse"],"prefix":"10.1002","volume":"12","author":[{"given":"G.","family":"Pastore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"de Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Acquaviva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Di","family":"Cordero Montezemolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Loiacono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tamaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"De BarbieriA: Investigation with synthetic antitumor peptides. In Proceedings of the VIth International Congress of Chemotherapy. Tokyo 1970 p146."},{"key":"e_1_2_1_3_2","unstructured":"De BarbieriA: Peptichemio: a synthesis of pharmacological morphological biochemical and biomolecular investigations. In Proceedings of the Symposium on Peptichemio. Milan 1972."},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820701)50:1<10::AID-CNCR2820500104>3.0.CO;2-9"},{"key":"e_1_2_1_5_2","first-page":"1015","article-title":"Peptichemio in childhood solid tumors","volume":"62","author":"Otten J","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_6_2","first-page":"290","article-title":"A phase\u2010II clinical trial of peptichemio","volume":"27","author":"Pommatau E","year":"1977","journal-title":"Biom\u00e9dicine"},{"key":"e_1_2_1_7_2","first-page":"190","article-title":"Peptichemio in the therapy of malignancies (a phase I study)","volume":"10","author":"Gingold N","year":"1974","journal-title":"Int J Pharmacol Biopharm"},{"key":"e_1_2_1_8_2","first-page":"385","article-title":"Clinical evaluation of peptichemio","volume":"63","author":"Grose WE","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800515)45:10<2524::AID-CNCR2820451010>3.0.CO;2-M"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950120303","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950120303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:15:18Z","timestamp":1697771718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950120303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,1]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984,1]]}},"alternative-id":["10.1002\/mpo.2950120303"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950120303","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,1]]}}}